Insumin500mg

Imeglimin Hydrochloride is a medicine used to treat type 2 diabetes mellitus. It helps control blood sugar levels and thus prevent serious complications of diabetes. It is also used to treat menstruation related disorder known as Polycystic ovary syndrome (PCOS) in women. Imeglimin Hydrochloride is best taken with food to avoid nausea and abdominal pain. You should take it regularly, at the same time each day, to get the most benefit. You should not stop taking this medicine unless your doctor recommends it. Your lifestyle plays a big part in controlling diabetes. Therefore, it is important to stay on the diet and exercise program recommended by your doctor while taking this medicine. The most common side effects of this medicine include nausea, vomiting, taste change, diarrhea, abdominal pain and loss of appetite. Some people may develop hypoglycemia (low blood sugar level) when this medicine is taken along with other antidiabetic medicines, alcohol or upon skipping a meal. Monitor your blood sugar levels regularly while taking it. Before taking this medicine, inform your doctor if you have any kidney, liver or heart problems. Pregnant or breastfeeding women should also consult their doctor before taking it. Your doctor will check your kidney function tests before starting treatment with it. Avoid excessive alcohol intake while taking it as this may increase the risk of developing some side effects. Imeglimin's mechanism of action involves dual effects: (a) amplification of glucose-stimulated insulin secretion (GSIS) and preservation of β-cell mass; and (b) enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle. At a cellular and molecular level, Imeglimin's underlying mechanism may involve correction of mitochondrial dysfunction, a common underlying element of T2D pathogenesis. It has been observed to rebalance respiratory chain activity (partial inhibition of Complex I and correction of deficient Complex III activity), resulting in reduced reactive oxygen species formation (decreasing oxidative stress) and prevention of mitochondrial permeability transition pore opening (implicated in preventing cell death). In islets derived from diseased rodents with T2D, Imeglimin also enhances glucose-stimulated ATP generation and induces the synthesis of nicotinamide adenine dinucleotide (NAD+) via the 'salvage pathway'. In addition to playing a key role as a mitochondrial co-factor, NAD+ metabolites may contribute to the increase in GSIS (via enhanced Ca++ mobilization). Imeglimin has also been shown to preserve β-cell mass in rodents with T2D. Overall, Imeglimin appears to target a key root cause of T2D: defective cellular energy metabolism. This potential mode of action is unique and has been shown to differ from that of other major therapeutic classes, including biguanides, sulphonylureas and glucagon-like peptide-1 receptor agonists.

Type 2 diabetes mellitus

_NAME_ mechanism of action involves dual effects: (a) amplification of glucose-stimulated insulin secretion (GSIS) and preservation of β-cell mass; and (b) enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle. At a cellular and molecular level, Imeglimin's underlying mechanism may involve correction of mitochondrial dysfunction, a common underlying element of T2D pathogenesis. It has been observed to rebalance respiratory chain activity (partial inhibition of Complex I and correction of deficient Complex III activity), resulting in reduced reactive oxygen species formation (decreasing oxidative stress) and prevention of mitochondrial permeability transition pore opening (implicated in preventing cell death). In islets derived from diseased rodents with T2D, _NAME_ also enhances glucose-stimulated ATP generation and induces the synthesis of nicotinamide adenine dinucleotide (NAD+) via the 'salvage pathway'. In addition to playing a key role as a mitochondrial co-factor, NAD+ metabolites may contribute to the increase in GSIS (via enhanced Ca++ mobilization)._NAME_ has also been shown to preserve β-cell mass in rodents with T2D. Overall, _NAME_ appears to target a key root cause of T2D: defective cellular energy metabolism. This potential mode of action is unique and has been shown to differ from that of other major therapeutic classes, including biguanides, sulphonylureas and glucagon-like peptide-1 receptor agonists.

Adult Dose: The usual adult dosage is 1000 mg of _NAME_ administered orally twice daily in the morning and evening. Child Dose: Not recommended. Renal Dose: It is safe to use in patients with kidney disease. No dose adjustment is recommended.

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Imeglimin Hydrochloride is to be taken with food.

If you miss a dose of _NAME_ Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.

Common side effects of _NAME_ Hypoglycemia (low blood glucose level) Constipation.

[CONSULT YOUR DOCTOR] It is not known whether Imeglimin Hydrochloride alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis). Renal failure, severe renal or hepatic impairment, acute conditions which may affect renal function e.g. dehydration, severe infection or shock. Cardiac failure, CHF, IDDM, severe impairment of thyroid function; acute or chronic alcoholism. Acute or chronic diseases which may cause tissue hypoxia e.g. cardiac or respiratory failure, recent MI or shock. Pregnancy, lactation.

Additive effect with _NAME_ . Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine. Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.

[UNSAFE] It is unsafe to consume alcohol with Imeglimin Hydrochloride.

[CONSULT YOUR DOCTOR] There isn't enough reliable information to know if Imeglimin Hydrochloride is safe to use when pregnant. Stay on the safe side and avoid use.

[CONSULT YOUR DOCTOR] There isn't enough reliable information to know if Imeglimin Hydrochloride is safe to use when breast feeding. Stay on the safe side and avoid use.

[CAUTION] Imeglimin Hydrochloride should be used with caution in patients with kidney disease. Dose adjustment of Imeglimin Hydrochloride may be needed. Please consult your doctor. Use of Imeglimin Hydrochloride is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine. [CAUTION] Imeglimin Hydrochloride should be used with caution in patients with liver disease. Dose adjustment of Imeglimin Hydrochloride may be needed. Please consult your doctor. Imeglimin Hydrochloride is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.